Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma
Sponsor: Capital Health System, Inc
Summary
The hypothesize that SBRT will limit or reverse tumor growth and thereby convert the borderline resectable disease or locally advanced disease in to a resectable tumor. Furthermore, we want to assess whether SBRT leads to an improved quality of life compared to IMRT.
Official title: Safety and Efficacy of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma: Open Label Prospective Randomized Clinical Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2021-06-22
Completion Date
2027-06-22
Last Updated
2023-03-31
Healthy Volunteers
No
Conditions
Interventions
Cyberknife
5-10 Gy/fraction.Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).
Locations (1)
Capital Health Medical Center-Hopewell
Pennington, New Jersey, United States